| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017944 | HBV | ENSG00000037280.16 | protein_coding | FLT4 | Yes | No | 2324 | P35916 |
| TVIS20039575 | HPV | ENSG00000037280.16 | protein_coding | FLT4 | Yes | No | 2324 | P35916 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FLT4 |
|---|---|
| DrugBank ID | DB04879 |
| Drug Name | Vatalanib |
| Target ID | BE0000023 |
| UniProt ID | P35916 |
| Regulation Type | |
| PubMed IDs | 17584317 |
| Citations | Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. |
| Groups | Investigational |
| Direct Classification | Phthalazines |
| SMILES | ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1 |
| Pathways | Vatalanib Action Pathway |
| PharmGKB | PA7001 |
| ChEMBL | CHEMBL101253 |
